nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—EIF4E—pancreas—gallbladder cancer	0.023	0.169	CbGeAlD
Sirolimus—EIF4E—liver—gallbladder cancer	0.0146	0.107	CbGeAlD
Sirolimus—MTOR—epithelium—gallbladder cancer	0.00997	0.0732	CbGeAlD
Sirolimus—FKBP1A—epithelium—gallbladder cancer	0.00897	0.0658	CbGeAlD
Sirolimus—MTOR—pancreas—gallbladder cancer	0.00888	0.0652	CbGeAlD
Sirolimus—FKBP1A—pancreas—gallbladder cancer	0.00799	0.0587	CbGeAlD
Sirolimus—FGF2—lymph node—gallbladder cancer	0.00683	0.0501	CbGeAlD
Sirolimus—CYP3A7—liver—gallbladder cancer	0.00629	0.0462	CbGeAlD
Sirolimus—MTOR—liver—gallbladder cancer	0.00565	0.0415	CbGeAlD
Sirolimus—CYP3A7-CYP3A51P—liver—gallbladder cancer	0.00535	0.0393	CbGeAlD
Sirolimus—FKBP1A—liver—gallbladder cancer	0.00508	0.0373	CbGeAlD
Sirolimus—SLC47A1—liver—gallbladder cancer	0.00437	0.0321	CbGeAlD
Sirolimus—MTOR—lymph node—gallbladder cancer	0.00433	0.0318	CbGeAlD
Sirolimus—SLCO1B1—liver—gallbladder cancer	0.00431	0.0317	CbGeAlD
Sirolimus—FKBP1A—lymph node—gallbladder cancer	0.0039	0.0286	CbGeAlD
Sirolimus—CYP3A5—pancreas—gallbladder cancer	0.00348	0.0255	CbGeAlD
Sirolimus—SLC47A1—lymph node—gallbladder cancer	0.00335	0.0246	CbGeAlD
Sirolimus—CYP3A5—liver—gallbladder cancer	0.00221	0.0163	CbGeAlD
Sirolimus—ABCB1—epithelium—gallbladder cancer	0.00207	0.0152	CbGeAlD
Sirolimus—ABCB1—pancreas—gallbladder cancer	0.00185	0.0136	CbGeAlD
Sirolimus—CYP3A4—liver—gallbladder cancer	0.00166	0.0122	CbGeAlD
Sirolimus—ABCB1—liver—gallbladder cancer	0.00118	0.00863	CbGeAlD
Sirolimus—MTOR—Insulin receptor signalling cascade—HRAS—gallbladder cancer	0.00106	0.00123	CbGpPWpGaD
Sirolimus—MTOR—IGF1R signaling cascade—HRAS—gallbladder cancer	0.00106	0.00123	CbGpPWpGaD
Sirolimus—FGF2—DAP12 signaling—KRAS—gallbladder cancer	0.00106	0.00123	CbGpPWpGaD
Sirolimus—EIF4E—Cytokine Signaling in Immune system—HRAS—gallbladder cancer	0.00106	0.00122	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR in disease—EGFR—gallbladder cancer	0.00106	0.00122	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—EGFR—gallbladder cancer	0.00106	0.00122	CbGpPWpGaD
Sirolimus—FGF2—Fc epsilon receptor (FCERI) signaling—EGFR—gallbladder cancer	0.00106	0.00122	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—ERBB4—gallbladder cancer	0.00105	0.00121	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR—EGFR—gallbladder cancer	0.00105	0.00121	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—ERBB2—gallbladder cancer	0.00105	0.00121	CbGpPWpGaD
Sirolimus—MTOR—Signaling by VEGF—KRAS—gallbladder cancer	0.00104	0.00121	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling events of B Cell Receptor (BCR)—KRAS—gallbladder cancer	0.00104	0.00121	CbGpPWpGaD
Sirolimus—MTOR—Signaling by Insulin receptor—KRAS—gallbladder cancer	0.00104	0.0012	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—ERBB2—gallbladder cancer	0.00104	0.0012	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR in Cancer—EGFR—gallbladder cancer	0.00104	0.0012	CbGpPWpGaD
Sirolimus—FGF2—Signaling by PDGF—EGFR—gallbladder cancer	0.00103	0.0012	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—NRAS—gallbladder cancer	0.00103	0.00119	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—NRAS—gallbladder cancer	0.00103	0.00119	CbGpPWpGaD
Sirolimus—FGF2—Signaling by SCF-KIT—HRAS—gallbladder cancer	0.00102	0.00118	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—ERBB2—gallbladder cancer	0.001	0.00116	CbGpPWpGaD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—TP53—gallbladder cancer	0.000999	0.00116	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR in disease—KRAS—gallbladder cancer	0.000997	0.00115	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—KRAS—gallbladder cancer	0.000997	0.00115	CbGpPWpGaD
Sirolimus—FGF2—Fc epsilon receptor (FCERI) signaling—KRAS—gallbladder cancer	0.000997	0.00115	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—EGFR—gallbladder cancer	0.000993	0.00115	CbGpPWpGaD
Sirolimus—MTOR—Immune System—KEAP1—gallbladder cancer	0.000993	0.00115	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—ERBB3—gallbladder cancer	0.000989	0.00114	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR—KRAS—gallbladder cancer	0.000988	0.00114	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—NRAS—gallbladder cancer	0.000987	0.00114	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR in Cancer—KRAS—gallbladder cancer	0.00098	0.00113	CbGpPWpGaD
Sirolimus—FGF2—B Cell Activation—EGFR—gallbladder cancer	0.000977	0.00113	CbGpPWpGaD
Sirolimus—FGF2—Signaling by PDGF—KRAS—gallbladder cancer	0.000975	0.00113	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling of activated FGFR—HRAS—gallbladder cancer	0.000973	0.00113	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—NRAS—gallbladder cancer	0.000971	0.00112	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB4—HRAS—gallbladder cancer	0.000957	0.00111	CbGpPWpGaD
Sirolimus—MTOR—ErbB1 downstream signaling—HRAS—gallbladder cancer	0.000955	0.00111	CbGpPWpGaD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—HRAS—gallbladder cancer	0.000955	0.00111	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—ERBB3—gallbladder cancer	0.000944	0.00109	CbGpPWpGaD
Sirolimus—MTOR—VEGFA-VEGFR2 Pathway—HRAS—gallbladder cancer	0.000941	0.00109	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—EGFR—gallbladder cancer	0.00094	0.00109	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—KRAS—gallbladder cancer	0.000938	0.00109	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—EGFR—gallbladder cancer	0.000935	0.00108	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—NRAS—gallbladder cancer	0.000928	0.00107	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—NRAS—gallbladder cancer	0.000923	0.00107	CbGpPWpGaD
Sirolimus—FGF2—B Cell Activation—KRAS—gallbladder cancer	0.000923	0.00107	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—NRAS—gallbladder cancer	0.000918	0.00106	CbGpPWpGaD
Sirolimus—FGF2—Downstream signal transduction—HRAS—gallbladder cancer	0.000914	0.00106	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—NRAS—gallbladder cancer	0.000914	0.00106	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR—HRAS—gallbladder cancer	0.00091	0.00105	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—ERBB3—gallbladder cancer	0.000906	0.00105	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB2—HRAS—gallbladder cancer	0.000905	0.00105	CbGpPWpGaD
Sirolimus—ABCB1—lymph node—gallbladder cancer	0.000901	0.00662	CbGeAlD
Sirolimus—FGF2—DAP12 signaling—HRAS—gallbladder cancer	0.000901	0.00104	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NRAS—gallbladder cancer	0.000901	0.00104	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—EGFR—gallbladder cancer	0.000899	0.00104	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—gallbladder cancer	0.00089	0.00103	CbGpPWpGaD
Sirolimus—MTOR—Signaling by VEGF—HRAS—gallbladder cancer	0.000888	0.00103	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling events of B Cell Receptor (BCR)—HRAS—gallbladder cancer	0.000888	0.00103	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—KRAS—gallbladder cancer	0.000888	0.00103	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—EGFR—gallbladder cancer	0.000885	0.00102	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—KRAS—gallbladder cancer	0.000883	0.00102	CbGpPWpGaD
Sirolimus—MTOR—Signaling by Insulin receptor—HRAS—gallbladder cancer	0.000882	0.00102	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NRAS—gallbladder cancer	0.00086	0.000995	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—NRAS—gallbladder cancer	0.00086	0.000995	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—NRAS—gallbladder cancer	0.00086	0.000995	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—NRAS—gallbladder cancer	0.000852	0.000987	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—KRAS—gallbladder cancer	0.000849	0.000983	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—HRAS—gallbladder cancer	0.000848	0.000981	CbGpPWpGaD
Sirolimus—FGF2—Fc epsilon receptor (FCERI) signaling—HRAS—gallbladder cancer	0.000848	0.000981	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR in disease—HRAS—gallbladder cancer	0.000848	0.000981	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—EGFR—gallbladder cancer	0.000845	0.000978	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—NRAS—gallbladder cancer	0.000845	0.000978	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—EGFR—gallbladder cancer	0.000841	0.000974	CbGpPWpGaD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—gallbladder cancer	0.000841	0.000974	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—NRAS—gallbladder cancer	0.000841	0.000974	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—KRAS—gallbladder cancer	0.00084	0.000973	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR—HRAS—gallbladder cancer	0.00084	0.000973	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—EGFR—gallbladder cancer	0.000837	0.000969	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—KRAS—gallbladder cancer	0.000836	0.000968	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—TP53—gallbladder cancer	0.000834	0.000965	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—EGFR—gallbladder cancer	0.000833	0.000964	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR in Cancer—HRAS—gallbladder cancer	0.000833	0.000964	CbGpPWpGaD
Sirolimus—FGF2—Signaling by PDGF—HRAS—gallbladder cancer	0.000829	0.00096	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—gallbladder cancer	0.000821	0.00095	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—ERBB4—gallbladder cancer	0.00081	0.000938	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—KRAS—gallbladder cancer	0.000798	0.000924	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—NRAS—gallbladder cancer	0.000796	0.000921	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—KRAS—gallbladder cancer	0.000794	0.00092	CbGpPWpGaD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—KRAS—gallbladder cancer	0.000794	0.00092	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—KRAS—gallbladder cancer	0.000791	0.000915	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—NRAS—gallbladder cancer	0.000789	0.000914	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—KRAS—gallbladder cancer	0.000787	0.000911	CbGpPWpGaD
Sirolimus—FGF2—B Cell Activation—HRAS—gallbladder cancer	0.000784	0.000908	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—EGFR—gallbladder cancer	0.000783	0.000907	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—EGFR—gallbladder cancer	0.000783	0.000907	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—gallbladder cancer	0.000783	0.000907	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—ERBB4—gallbladder cancer	0.000778	0.000901	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—EGFR—gallbladder cancer	0.000776	0.000899	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—gallbladder cancer	0.000775	0.000898	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—ERBB4—gallbladder cancer	0.000775	0.000897	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—ERBB2—gallbladder cancer	0.00077	0.000891	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—EGFR—gallbladder cancer	0.00077	0.000891	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—EGFR—gallbladder cancer	0.000766	0.000887	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—gallbladder cancer	0.000762	0.000882	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—HRAS—gallbladder cancer	0.000755	0.000874	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—HRAS—gallbladder cancer	0.000751	0.000869	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—TP53—gallbladder cancer	0.000747	0.000865	CbGpPWpGaD
Sirolimus—MTOR—BDNF signaling pathway—HRAS—gallbladder cancer	0.000742	0.000859	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—KRAS—gallbladder cancer	0.00074	0.000857	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—KRAS—gallbladder cancer	0.00074	0.000857	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KRAS—gallbladder cancer	0.00074	0.000857	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—ERBB4—gallbladder cancer	0.00074	0.000856	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—KRAS—gallbladder cancer	0.000733	0.000849	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—KRAS—gallbladder cancer	0.000727	0.000842	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—EGFR—gallbladder cancer	0.000725	0.000839	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—KRAS—gallbladder cancer	0.000724	0.000838	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—HRAS—gallbladder cancer	0.000722	0.000836	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—EGFR—gallbladder cancer	0.000719	0.000833	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—HRAS—gallbladder cancer	0.000711	0.000823	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—ERBB3—gallbladder cancer	0.0007	0.000811	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—gallbladder cancer	0.000694	0.000803	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—KRAS—gallbladder cancer	0.000685	0.000793	CbGpPWpGaD
Sirolimus—MTOR—Insulin Signaling—HRAS—gallbladder cancer	0.000682	0.00079	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—KRAS—gallbladder cancer	0.000679	0.000786	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—HRAS—gallbladder cancer	0.000679	0.000786	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—HRAS—gallbladder cancer	0.000675	0.000782	CbGpPWpGaD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—gallbladder cancer	0.000675	0.000782	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—ERBB3—gallbladder cancer	0.000673	0.000779	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—HRAS—gallbladder cancer	0.000672	0.000778	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—ERBB2—gallbladder cancer	0.00067	0.000776	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—ERBB3—gallbladder cancer	0.00067	0.000775	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—HRAS—gallbladder cancer	0.000669	0.000774	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—gallbladder cancer	0.000659	0.000763	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—gallbladder cancer	0.000655	0.000759	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—ERBB3—gallbladder cancer	0.000639	0.00074	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—BCL2—gallbladder cancer	0.000638	0.000739	CbGpPWpGaD
Sirolimus—FGF2—Immune System—ERBB4—gallbladder cancer	0.000636	0.000736	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—gallbladder cancer	0.000629	0.000728	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—HRAS—gallbladder cancer	0.000629	0.000728	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—HRAS—gallbladder cancer	0.000629	0.000728	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—HRAS—gallbladder cancer	0.000623	0.000722	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—ERBB2—gallbladder cancer	0.00062	0.000718	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—HRAS—gallbladder cancer	0.000618	0.000715	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—HRAS—gallbladder cancer	0.000615	0.000712	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—BCL2—gallbladder cancer	0.000609	0.000705	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—ERBB2—gallbladder cancer	0.000592	0.000685	CbGpPWpGaD
Sirolimus—FGF2—Disease—ERBB4—gallbladder cancer	0.000587	0.00068	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—NRAS—gallbladder cancer	0.000586	0.000678	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—HRAS—gallbladder cancer	0.000582	0.000674	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—HRAS—gallbladder cancer	0.000577	0.000668	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—ERBB2—gallbladder cancer	0.000568	0.000658	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—gallbladder cancer	0.000557	0.000645	CbGpPWpGaD
Sirolimus—FGF2—Immune System—ERBB3—gallbladder cancer	0.00055	0.000636	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—ERBB4—gallbladder cancer	0.000542	0.000628	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—EGFR—gallbladder cancer	0.000534	0.000618	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—NRAS—gallbladder cancer	0.00051	0.00059	CbGpPWpGaD
Sirolimus—FGF2—Disease—ERBB3—gallbladder cancer	0.000508	0.000588	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—KRAS—gallbladder cancer	0.000504	0.000584	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—TP53—gallbladder cancer	0.000478	0.000553	CbGpPWpGaD
Sirolimus—MTOR—Immune System—ERBB4—gallbladder cancer	0.000472	0.000546	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—NRAS—gallbladder cancer	0.000472	0.000546	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—gallbladder cancer	0.000471	0.000546	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—ERBB3—gallbladder cancer	0.000469	0.000543	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—EGFR—gallbladder cancer	0.000464	0.000538	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—gallbladder cancer	0.000458	0.00053	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—BCL2—gallbladder cancer	0.000452	0.000523	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—NRAS—gallbladder cancer	0.00045	0.000521	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—ERBB2—gallbladder cancer	0.000439	0.000508	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—KRAS—gallbladder cancer	0.000439	0.000508	CbGpPWpGaD
Sirolimus—MTOR—Disease—ERBB4—gallbladder cancer	0.000436	0.000504	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—NRAS—gallbladder cancer	0.000432	0.0005	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—EGFR—gallbladder cancer	0.00043	0.000498	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—HRAS—gallbladder cancer	0.000429	0.000496	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—ERBB2—gallbladder cancer	0.000422	0.000488	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—ERBB2—gallbladder cancer	0.00042	0.000486	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ERBB4—gallbladder cancer	0.000411	0.000476	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—EGFR—gallbladder cancer	0.00041	0.000475	CbGpPWpGaD
Sirolimus—MTOR—Immune System—ERBB3—gallbladder cancer	0.000408	0.000472	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—KRAS—gallbladder cancer	0.000406	0.00047	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—ERBB2—gallbladder cancer	0.000401	0.000464	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—EGFR—gallbladder cancer	0.000394	0.000456	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—KRAS—gallbladder cancer	0.000387	0.000449	CbGpPWpGaD
Sirolimus—MTOR—Disease—ERBB3—gallbladder cancer	0.000377	0.000436	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—HRAS—gallbladder cancer	0.000373	0.000432	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—KRAS—gallbladder cancer	0.000372	0.000431	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ERBB3—gallbladder cancer	0.000355	0.000411	CbGpPWpGaD
Sirolimus—FGF2—Immune System—BCL2—gallbladder cancer	0.000355	0.000411	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—HRAS—gallbladder cancer	0.000345	0.000399	CbGpPWpGaD
Sirolimus—FGF2—Immune System—ERBB2—gallbladder cancer	0.000345	0.000399	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—NRAS—gallbladder cancer	0.000334	0.000387	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—HRAS—gallbladder cancer	0.000329	0.000381	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—NRAS—gallbladder cancer	0.000321	0.000371	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—NRAS—gallbladder cancer	0.000319	0.00037	CbGpPWpGaD
Sirolimus—FGF2—Disease—ERBB2—gallbladder cancer	0.000318	0.000368	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—gallbladder cancer	0.000317	0.000367	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—HRAS—gallbladder cancer	0.000316	0.000366	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ERBB4—gallbladder cancer	0.000305	0.000353	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—NRAS—gallbladder cancer	0.000305	0.000353	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—EGFR—gallbladder cancer	0.000304	0.000352	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—gallbladder cancer	0.0003	0.000347	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—ERBB2—gallbladder cancer	0.000294	0.00034	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—EGFR—gallbladder cancer	0.000292	0.000338	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—EGFR—gallbladder cancer	0.000291	0.000337	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—KRAS—gallbladder cancer	0.000288	0.000333	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—EGFR—gallbladder cancer	0.000278	0.000322	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—KRAS—gallbladder cancer	0.000276	0.00032	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—KRAS—gallbladder cancer	0.000275	0.000318	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—gallbladder cancer	0.000266	0.000308	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ERBB3—gallbladder cancer	0.000264	0.000305	CbGpPWpGaD
Sirolimus—MTOR—Immune System—BCL2—gallbladder cancer	0.000263	0.000305	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—KRAS—gallbladder cancer	0.000262	0.000304	CbGpPWpGaD
Sirolimus—FGF2—Immune System—NRAS—gallbladder cancer	0.000262	0.000304	CbGpPWpGaD
Sirolimus—MTOR—Immune System—ERBB2—gallbladder cancer	0.000256	0.000296	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—HRAS—gallbladder cancer	0.000244	0.000283	CbGpPWpGaD
Sirolimus—FGF2—Disease—NRAS—gallbladder cancer	0.000242	0.00028	CbGpPWpGaD
Sirolimus—FGF2—Immune System—EGFR—gallbladder cancer	0.000239	0.000277	CbGpPWpGaD
Sirolimus—MTOR—Disease—ERBB2—gallbladder cancer	0.000236	0.000273	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—HRAS—gallbladder cancer	0.000235	0.000272	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—HRAS—gallbladder cancer	0.000234	0.000271	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—gallbladder cancer	0.000233	0.00027	CbGpPWpGaD
Sirolimus—FGF2—Immune System—KRAS—gallbladder cancer	0.000226	0.000261	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—NRAS—gallbladder cancer	0.000224	0.000259	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—HRAS—gallbladder cancer	0.000223	0.000258	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ERBB2—gallbladder cancer	0.000223	0.000258	CbGpPWpGaD
Sirolimus—FGF2—Disease—EGFR—gallbladder cancer	0.000221	0.000255	CbGpPWpGaD
Sirolimus—FGF2—Disease—KRAS—gallbladder cancer	0.000208	0.000241	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—EGFR—gallbladder cancer	0.000204	0.000236	CbGpPWpGaD
Sirolimus—MTOR—Immune System—NRAS—gallbladder cancer	0.000195	0.000225	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—KRAS—gallbladder cancer	0.000193	0.000223	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HRAS—gallbladder cancer	0.000192	0.000222	CbGpPWpGaD
Sirolimus—MTOR—Disease—NRAS—gallbladder cancer	0.00018	0.000208	CbGpPWpGaD
Sirolimus—MTOR—Immune System—EGFR—gallbladder cancer	0.000177	0.000205	CbGpPWpGaD
Sirolimus—FGF2—Disease—HRAS—gallbladder cancer	0.000177	0.000205	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—gallbladder cancer	0.000171	0.000198	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NRAS—gallbladder cancer	0.00017	0.000196	CbGpPWpGaD
Sirolimus—MTOR—Immune System—KRAS—gallbladder cancer	0.000167	0.000194	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ERBB2—gallbladder cancer	0.000165	0.000191	CbGpPWpGaD
Sirolimus—MTOR—Disease—EGFR—gallbladder cancer	0.000164	0.000189	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HRAS—gallbladder cancer	0.000164	0.000189	CbGpPWpGaD
Sirolimus—MTOR—Disease—KRAS—gallbladder cancer	0.000155	0.000179	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EGFR—gallbladder cancer	0.000154	0.000179	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—KRAS—gallbladder cancer	0.000146	0.000169	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HRAS—gallbladder cancer	0.000142	0.000165	CbGpPWpGaD
Sirolimus—MTOR—Disease—HRAS—gallbladder cancer	0.000131	0.000152	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—gallbladder cancer	0.00013	0.00015	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NRAS—gallbladder cancer	0.000126	0.000146	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HRAS—gallbladder cancer	0.000124	0.000144	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EGFR—gallbladder cancer	0.000115	0.000133	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KRAS—gallbladder cancer	0.000108	0.000125	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—gallbladder cancer	9.62e-05	0.000111	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HRAS—gallbladder cancer	9.2e-05	0.000107	CbGpPWpGaD
